Clinical Trials

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma


Study ID
GCT3013-01

NCT Number
NCT03625037 (Click on the NCT number for more information about the trial)

Principle Investigator
Dr. Feldman, Tatyana

Phase
I/II

Sponsor
Genmab US, Inc


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now